Pheochromocytoma classification: Difference between revisions
Asem Juhani (talk | contribs) No edit summary |
Asem Juhani (talk | contribs) |
||
| Line 30: | Line 30: | ||
==== Familial pheochromocytoma ==== | ==== Familial pheochromocytoma ==== | ||
* Familial pheochromocytoma is associated with | * Familial pheochromocytoma is associated with several hereditary disorders including Multiple Endocrine Neoplasia types 2A and 2B ([[Multiple endocrine neoplasia type 2|MEN2]]) (caused by mutations of the RET gene), von Hippel-Lindau (VHL) disease (caused by mutations of the VHL gene), familial paraganglioma of the neck (cause by mutations of the gene for succinate dehydrogenase subunit D (SDHD)) and neurofibromatosis type 1 (NF1). | ||
==== Non-familial pheochromocytoma: ==== | ==== Non-familial pheochromocytoma: ==== | ||
* Resulting from sporadic germ-line mutations, which have been documented in about 20% of cases. | |||
* The majority of them are positive for [[C-kit|KIT]] expression, some are not. A partial explanation was provided by the finding of activating mutations in another gene encoding an RTK, the [[Platelet-derived growth factor receptor|platelet-derived growth factor receptor alpha]] (''PDGFRA'') gene in some [[Gastrointestinal stromal tumor|KIT-negative GISTs]]: | * The majority of them are positive for [[C-kit|KIT]] expression, some are not. A partial explanation was provided by the finding of activating mutations in another gene encoding an RTK, the [[Platelet-derived growth factor receptor|platelet-derived growth factor receptor alpha]] (''PDGFRA'') gene in some [[Gastrointestinal stromal tumor|KIT-negative GISTs]]: | ||
Revision as of 16:55, 8 February 2019
|
Pheochromocytoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pheochromocytoma classification On the Web |
|
American Roentgen Ray Society Images of Pheochromocytoma classification |
|
Risk calculators and risk factors for Pheochromocytoma classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmad Al Maradni, M.D. [2] Mohammed Abdelwahed M.D[3]
Overview
Pheochromocytomas and paragangliomas (collectively referred to as PPGLs) are rare tumors that originate from chromaffin cells in the adrenal medulla (pheochromocytoma) or in the extra-adrenal neural ganglia (paraganglioma). These tumors can be either biochemically active (producing a catecholamine like epinephrine, nor-epinephrine and dopamine) or biochemically silent. PPGLs can be either sporadic or genetic, with association to several familial syndromes.
PPGLs can also be classified according to their spread into local, regional, or metastatic. The definition of malignancy in PPGLs is the presence of metastasis.
Classification
Classification based on nature of tumor:
Malignant and benign tumors share the same biochemical and histological characters. The only difference is the ability of the malignant tumor to metastasize to distant tissues. Long-term follow up is recommended in most cases due to high rates of recurrence.
Classification based on spread:
- Localized:
- 95% of pheochromocytomas are found in the abdomen
- 85 to 90 % are intra-adrenal
- 5 to 10 percent are multiple
- 15-20% of PPGLs are extra-adrenal (paragangliomas).
- Regional
- Metastatic: common sites of metastasis include:
Classification based on genetics:
Familial pheochromocytoma
- Familial pheochromocytoma is associated with several hereditary disorders including Multiple Endocrine Neoplasia types 2A and 2B (MEN2) (caused by mutations of the RET gene), von Hippel-Lindau (VHL) disease (caused by mutations of the VHL gene), familial paraganglioma of the neck (cause by mutations of the gene for succinate dehydrogenase subunit D (SDHD)) and neurofibromatosis type 1 (NF1).
Non-familial pheochromocytoma:
- Resulting from sporadic germ-line mutations, which have been documented in about 20% of cases.
- The majority of them are positive for KIT expression, some are not. A partial explanation was provided by the finding of activating mutations in another gene encoding an RTK, the platelet-derived growth factor receptor alpha (PDGFRA) gene in some KIT-negative GISTs:
Sporadic:
- Most catecholamine-secreting tumors are sporadic. Mutations have been identified in most of the sporadic cases.
- May be due to spontaneous mutation, decreased penetrance or maternal imprinting.[1]
- 50% of patients had a pathogenic mutation in SDHB, SDHD, or VHL.[2]
References
- ↑ Buffet A, Venisse A, Nau V, Roncellin I, Boccio V, Le Pottier N; et al. (2012). "A decade (2001-2010) of genetic testing for pheochromocytoma and paraganglioma". Horm Metab Res. 44 (5): 359–66. doi:10.1055/s-0032-1304594. PMID 22517557.
- ↑ Jafri M, Whitworth J, Rattenberry E, Vialard L, Kilby G, Kumar AV; et al. (2013). "Evaluation of SDHB, SDHD and VHL gene susceptibility testing in the assessment of individuals with non-syndromic phaeochromocytoma, paraganglioma and head and neck paraganglioma". Clin Endocrinol (Oxf). 78 (6): 898–906. doi:10.1111/cen.12074. PMID 23072324.